# US 2025/0375492 A1 · Monascus pilosus strain, composition for preventing or treating nonalcoholic fatty liver disease and use of said monascus pilosus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375492 A1
- Document ID: US20250375492A1
- Status: Published application
- Kind: A1
- Application number: 18/904,045
- Filed: 2024-10-01
- Published: 2025-12-11
- Earliest claimed: 2024-06-07
- Assignees: Sunway Biotech Co., Ltd.
- Applicants: Sunway Biotech Co., Ltd.
- Inventors: CHUN-LIN LEE; TZU-MING PAN; CHIA YUEH PAN; YA-WEN HSU
- Web page: https://patentgrep.com/patent/US20250375492A1

## CPC

- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 36/062: Ascomycota
- A61K 31/365: Lactones
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The main purpose of the present invention is to provide a Monascus pilosus strain and a composition for preventing or treating nonalcoholic fatty liver disease. The composition comprises Monascus pilosus and/or its fermented product, or comprises an active ingredient of its fermented product. Another objective of the present invention is to provide a use of Monascus pilosus in the manufacture of a composition for the prevention or treatment of nonalcoholic fatty liver disease. The composition of the present invention not only has the efficacy of reducing the accumulation of TC (total cholesterol) and TG (triglycerides) caused by obesity-related nonalcoholic fatty liver disease (NAFLD) but also has the efficacy of reducing serum liver function markers Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT). Therefore, the composition of the present invention has the potential for preventing or treating nonalcoholic fatty liver and metabolic diseases such as hyperlipidemia.

## Claims

### Claim 1

A Monascus pilosus, deposited at the National Collections of Industrial, Food and Marine Bacteria (NCIMB Ltd) under the Accession Number NCIMB 44103.

### Claim 2

A use of a Monascus pilosus in the manufacture of a composition for preventing or treating nonalcoholic fatty liver disease, wherein the Monascus pilosus may be the Monascus pilosus deposited at the National Collections of Industrial, Food and Marine Bacteria (NCIMB Ltd) under the Accession Number NCIMB 44103.

### Claim 3

A composition for preventing or treating nonalcoholic fatty liver disease, comprising an active ingredient with an effective amount, wherein the active ingredient is extracted from a Monascus pilosus fermented product, the Monascus pilosus fermented product is prepared by fermenting a base material by a Monascus pilosus, and the Monascus pilosus may be the Monascus pilosus deposited at the National Collections of Industrial, Food and Marine Bacteria (NCIMB Ltd) under the Accession Number NCIMB 44103.

### Claim 4 (depends on 3)

The composition according to claim 3, wherein the nonalcoholic fatty liver disease is caused by at least one condition selected from the group consisting of obesity, hypertension, hyperlipidemia, and diabetes.

### Claim 5 (depends on 3)

The composition according to claim 3, wherein the composition reduces serum liver function indices AST and ALT.

### Claim 6 (depends on 3)

The composition according to claim 3, wherein the composition inhibits the accumulation of fat in liver tissue.

### Claim 7 (depends on 3)

The composition according to claim 3, wherein the composition reduces the levels of total cholesterol (TC) and triglycerides (TG) in liver.

### Claim 8 (depends on 3)

The composition according to claim 3, wherein the composition improves liver lipid droplet accumulation and fatty infiltration.

### Claim 9 (depends on 3)

The composition according to claim 3, wherein the composition is capable of enhancing abundance of beneficial intestinal flora and changing gut microbiota composition.

### Claim 10 (depends on 3)

The composition according to claim 3, wherein the active ingredient comprises at least one selected from the group consisting of Monascinol, Ankaflavin and Monascin.

### Claim 11 (depends on 3)

The composition according to claim 3, wherein the base material is a rice, dioscoreae rhizoma, or mixture of related carbohydrates.

### Claim 12 (depends on 3)

The composition according to claim 3, wherein the effective amount when used alone is at least 1.5 mg to 12 mg per day for adults.

### Claim 13

A composition for preventing or treating nonalcoholic fatty liver disease, comprising a Monascus pilosus fermented product with an effective amount, wherein the Monascus pilosus fermented product is prepared by fermenting a base material by a Monascus pilosus, and the Monascus pilosus may be the Monascus pilosus deposited at the National Collections of Industrial, Food and Marine Bacteria (NCIMB Ltd) under the Accession Number NCIMB 44103.

### Claim 14 (depends on 13)

The composition according to claim 13, wherein the nonalcoholic fatty liver disease is caused by at least one condition selected from the group consisting of obesity, hypertension, hyperlipidemia, and diabetes.

### Claim 15 (depends on 13)

The composition according to claim 13, wherein the composition reduces serum liver function indices AST and ALT.

### Claim 16 (depends on 13)

The composition according to claim 13, wherein the composition inhibits the accumulation of fat in liver tissue.

### Claim 17 (depends on 13)

The composition according to claim 13, wherein the composition reduces the levels of total cholesterol (TC) and triglycerides (TG) in liver.

### Claim 18 (depends on 13)

The composition according to claim 13, wherein the composition improves liver lipid droplet accumulation and fatty infiltration.

### Claim 19 (depends on 13)

The composition according to claim 13, wherein the composition is capable of enhancing abundance of beneficial intestinal flora and changing gut microbiota composition.

### Claim 20 (depends on 13)

The composition according to claim 13, wherein the base material is a rice, dioscoreae rhizoma, or mixture of related carbohydrates.

### Claim 21 (depends on 13)

The composition according to claim 13, wherein the effective amount is at least 0.5 g per day for adults and containing 1.5 mg of monascinol.

### Claim 22 (depends on 13)

The composition according to claim 13, wherein the Monascus pilosus fermented product comprises at least one active ingredient, and the active ingredient is at least one selected from the group consisting of Monascinol, Ankaflavin and Monascin.

### Claim 23 (depends on 13)

The composition according to claim 13, wherein the composition is a food composition, a pharmaceutical composition, a feed composition, a nutritional supplement composition, a dietary supplement composition, or a food additive composition.
